Phase 1 Trial of GCC19CART Shows 80% Objective Response Rate in Metastatic Colorectal Cancer at ASCO GI Symposium

Jan 21, 2025 20:30 CST Updated 20:30

ICT

Oncology Drug Developer

Guide

From January 23 to 25, 2025, the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO Gastrointestinal Cancers Symposium) will be held in San Francisco, USA. The American Society of Clinical Oncology (ASCO) is one of the most influential professional oncology academic organizations globally, and its Gastrointestinal Cancers Symposium is a specialized academic conference in the field of gastrointestinal tumors, focusing on cutting-edge theories and research achievements in the treatment and care of gastrointestinal cancers.

ICT (referred to as "Si Dan Sai" below) is a clinical-stage biotechnology company focused on developing CAR-T cell therapy products for solid tumors. The company's research abstract on the leading therapy for solid tumors, GCC19CART, has been honored with selection for presentation at this year’s ASCO Gastrointestinal Cancers Symposium. The abstract was submitted by Dr. Bridget Keenan, Co-Director of the Cancer Immunotherapy Program at the UCSF (University of California, San Francisco) Cancer Center, one of the U.S. clinical trial sites for GCC19CART, and it discloses the latest progress from the U.S. clinical trial CARAPIA-1 of GCC19CART. The abstract will be presented in poster format, with an on-site explanation by Dr. Keenan.

GCC19CART is the first candidate product developed by ICT based on its self-developed novel CAR-T technology — the CoupledCAR platform technology, intended for treating patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC).

ICT Participation Information:

Abstract Title: A Phase 1 Dose-Escalation Study of GCC19CART: A Novel CAR T-Cell Therapy for Metastatic Colorectal Cancer in the United States (A Phase 1 Dose-Escalation Study of GCC19CART: A Novel CAR T-Cell Therapy for Metastatic Colorectal Cancer in the United States)
Meeting Location: Moscone West • San Francisco
Presentation Time: January 25, 2025, 7:00 AM - 7:55 AM (Local Time)
Poster Session: Cancers of the Colon, Rectum, and Anus
Abstract No.: 175
Reporter:Bridget Keenan, M.D.,UCICT Tumor CenterCo-Director of Cancer Immunotherapy Program

About ICT

ICT is a clinical-stage biotechnology company focused on developing CAR-T cell therapy products for solid tumors. ICT's unique CoupledCAR platform technology aims to overcome key challenges in treating solid tumors, and CAR-T products developed based on this platform have already achieved promising clinical outcomes in the treatment of advanced solid tumors such as colorectal cancer and prostate cancer. The company’s CAR-T cell therapy product for advanced colorectal cancer, GCC19CART, has received clinical trial approval and Fast Track designation from the U.S. Food and Drug Administration (FDA). The U.S. clinical trial, CARAPIA-1, is currently ongoing, with the clinical trial identifier: NCT05319314. ICT is also advancing a robust pipeline of CAR-T candidates targeting other solid tumors, including prostate cancer and pancreatic cancer. For more information, please visitwww.ictbio.com。

Investor Contact Information

Email: ir@ictbioinc.com

Contact Number: 021-58959719